Becca Valle's glioblastoma diagnosis came with only one warning sign: debilitating headaches that began in September 2021. The 37-year-old marathon runner initially thought she had migraines, but a hospital scan revealed blood in her brain. Doctors discovered a tumor and performed two craniotomies, removing what turned out to be glioblastoma, an aggressive brain cancer with a grim prognosis.

Glioblastoma patients face steep odds, with only about 10% surviving more than five years after diagnosis. The disease's treatment is complicated by the blood-brain barrier, which blocks most medications from reaching the brain. Valle enrolled in a clinical trial studying focused ultrasound technology that temporarily opens this barrier, allowing chemotherapy drugs to penetrate brain tissue more effectively. The treatment involves wearing a device that delivers sound waves to activate microbubbles, creating temporary openings in the blood-brain barrier.

Results from the trial showed promising outcomes, with up to 40% of participants still alive months later compared to expected survival rates. Lead researcher Dr. Graeme Woodworth compared these patients to a larger control group receiving standard chemotherapy alone, finding evidence of improved survival and tumor control. The treatment proved safe with no significant side effects reported by participants like Valle.

Four years after her diagnosis, Valle remains cancer-free, describing herself as "truly an outlier." She continues living actively, planning ski trips and maintaining her positive outlook while undergoing only biannual MRIs. The University of Maryland Medical Center is pursuing FDA approval for the focused ultrasound device, which could revolutionize treatment options for glioblastoma patients if approved for clinical use.

Quick Fact: Only about 10% of glioblastoma patients live more than five years after diagnosis.